Up to $10 million in cancer research funding available through ACRF
The Australian Cancer Research Foundation (ACRF) has begun accepting applications for their 2013 annual Cancer Research Grant Round.
The ACRF provides major grants between $1.5 and $5 million to develop state-of-the-art collaborative research centres and purchase advanced technologies and equipment. Grants of this magnitude are not available from any other private funding body in Australia.
The CEO of the ACRF, David Brettell, said, “Our grants fund truly world-class research and we’re prepared to award up to $5 million for any single initiative which has the potential to deliver outstanding results.”
The ACRF funds research in Australia that has the power to make significant breakthroughs in cancer diagnosis and treatment. Some of the biggest research outcomes made possible through ACRF funding are the cervical cancer vaccine, co-developed by Professor Ian Frazer AC, and the dedicated genetic research laboratory housed within the newly opened Kinghorn Cancer Centre in Sydney.
Executive Director of the Garvan Institute of Medical Research and recipient of $5 million in ACRF funds Professor John Mattick has said, “The significant funding that the ACRF provides for advanced technologies and infrastructure, which is rarely available elsewhere, empowers visionary research teams to rapidly advance our understanding, and treatments for, cancer.”
The ACRF is a ‘seed’ funding body and is interested in applications for larger-scale research projects whose value is over and above the amount sought directly from ACRF.
All applications for grants are considered and assessed by the standards of the ACRF’s Medical Research Advisory Committee (MRAC), a group of highly distinguished cancer scientists. The MRAC’s recommendations for funding are then reviewed and finalised by the foundation’s Board of Trustees.
The 2013 Cancer Research Grant Round closes on 10 May 2013. Applicants will be short-listed for further assessment in the following month.
For more information about the ACRF’s Cancer Research Grants, please visit http://www.acrf.com.au/cancer-research-grants/.
Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO
To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...
Optics11 Life appoints Jacquelien ten Dam as CEO
Optics11 Life plans to accelerate its commercial growth in key markets while building strategic...
Epilepsy pioneer elected President of Aust Academy of Science
Laureate Professor Sam Berkovic — one of the world's most respected neurologists...
